Abstract
Secondary hyperparathyroidism resulting in osteitis fibrosa is the most common bone abnormality observed in dialysis patients. Most recent data strongly suggest that a deficit of calcitriol is an important factor in the high parathyroid hormone (PTH) levels of these patients (1, 2). Thus, it is not surprising that the administration of calcitriol orally (3, 4) has resulted in the amelioration or even dramatic improvement of secondary hyperparathyroidism. What makes the use of intravenous calcitriol an attractive modality of therapy is the recent observation that calcitriol per se, in the absence of hypercalcemia inhibit both synthesis and secretion of PTH (5, 6). In the present chapter we will briefly review the physiological action of calcitriol in dialysis patients in regard to divalent ion metabolism, then we will discuss new data on calcitriol and PTH interaction and finally, the available clinical data on the intravenous use of calcitriol will be reviewed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Wilson L, Felsenfeld A, Drezner MK, Llach F: Altered divalent ion metabolism in early renal failure: role of 1,25(OH)2D. Kidney Int, 27: 565–573, 1985.
Llach F, Massry SG: On the mechanism of secondary hyperparathyroidism in moderate renal insufficiency. J Clin Endocrinol Metab, 61: 601–606, 1985.
Brickman AS, Coburn JW, Norman AW: Action of 1,25-dihydroxycholecalciferol, a potent, kidney-produced metabolite of vitamin D3 in uremic man. N Engl J Med, 287: 891–895, 1972.
Chan JCM, Oldham SB, Holick MF et al: Alpha hydroxyvitamin D3 in chronic renal failure: A potent analogue of the kidney hormone 1,25 dihydroxycholecalciferol. JAMA, 234: 47–52, 1975.
Silver J, Naveh-Many T, Mayer H, Schmelzer HJ, Popovtzer MM: Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J. Clin Invest, 78: 1296–1301, 1986.
Russell J, Lettieri D, Sherwood LM: Suppression by 1,25 (OH)2D3 of transcription of the pre-proparathyroid hormone gene. Endocrinology, 119: 2864–2866, 1986.
Kanis JA, Cundy J, Smith R et al: Possible function of different renal metabolites of vitamin D in man. Contrib Nephrol, 18: 192–211, 1980.
Henderson RG, Ledingham JGG, Oliver DO et al: Effects of 1,25 dihydroxycholecalciferol on calcium absorption, muscle weakness, and bone disease in chronic renal failure. Lancet, I: 379–384, 1974.
Coburn JW et al: Intestinal phosphate absorption in normal and uremic man: Effects of l,25(OH)2 vitamin D3 and l(OH) vitamin D3. In: “Phosphate Metabolism” (Eds SG Massry, E Ritz), Plenum Press, New York, 1977, p 549.
Coburn JW et al: Clinical efficacy of 1,25 di-hydroxyvitamin D3 in renal osteodystrophy. In: “Vitamin D: Biochemical, Chemical and Clinical Aspects Related to Calcium Metabolism” (Eds AW Norman et al), Walter de Gruyter, Berlin, 1977, p 657.
Silver J, Naveh-Many T, Mayer H, Schmelzer HJ, Popovtzer MM: Regulation by vitamin D Metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest, 78: 1296–1301, 1986.
Silver J, Russell J, Sherwood LM: Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. Proc Natl Sci, 82: 4270–4273, 1985.
Shuil Y, Naveh-Many T, Barach P, Silver J: Regulation of parathyroid cell gene expression in experimental uremia. J Am Soc Nephrol, 1: 99–104, 1990.
Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ: Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest, 74: 2136–2140, 1984.
Delmez JA, Tindira C, Grooms P, Dusso A, Windus DW, Slatopolsky E: Parathyroid hormone suppression by 1,25-dihydroxyvitamin D. A role for increased sensitivity to calcium. J Clin Invest, 83: 1349–1355, 1989.
Dunlay R, Rodriguez M, Felsenfeld AJ, Llach F: Direct inhibitory effect of calcitriol on parathyroid function (sigmoidal curve) in dialysis. Kidney Int, 36: 1093–1098, 1989.
Norris KC, Kraut JA, Andress DL, Agre KL, Sherrard DJ, Coburn JW: Intravenous calcitriol: Effect in severe secondary hyperparathyroidism. J Bone Mineral Research, 1(Suppl 1): 374, 1986.
Andress DL, Norris KC, Coburn JW, Slatopolsky E, Sherrard DJ: Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med, 321: 274–279, 1989.
Hamdy NAT, Brown CB, Kanis JA: Intravenous calcitriol lowers serum calcium concentrations in uremic patients with severe hyperparathyroidism and hypercalcemia. Nephrol Dial Transplant, 4: 545–548, 1989.
Brandi L, Daugaad H, Tvedegaard E, Storni T, Olgaard K: Effect of intravenous 1-alpha-hydroxyvitamin D3 on secondary hyperparathyroidism in chronic uremic patients on maintenance hemodialysis. Nephron, 53: 194–200, 1989.
Llach F: Parathyroidectomy in chronic renal failure: Indications, surgical approach and the use of calcitriol. Kidney Int, 38(Suppl 29): 62–68, 1990.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer-Verlag London Limited
About this chapter
Cite this chapter
Llach, F. (1991). Treatment of Secondary Hyperparathyroidism by Intravenous Calcitriol. In: Andreucci, V.E., Fine, L.G. (eds) International Yearbook of Nephrology 1992. Springer, London. https://doi.org/10.1007/978-1-4471-1892-3_11
Download citation
DOI: https://doi.org/10.1007/978-1-4471-1892-3_11
Publisher Name: Springer, London
Print ISBN: 978-1-4471-1894-7
Online ISBN: 978-1-4471-1892-3
eBook Packages: Springer Book Archive